Barclays Maintains Overweight on Boston Scientific, Lowers Price Target to $96

Benzinga Newsdesk www.benzinga.com Negative 85.2%

Neg 85.2% Neu 0% Pos 0%

Barclays analyst Matt Miksic maintains Boston Scientific (NYSE:BSX) with a Overweight and lowers the price target from $100 to $96.